Altimmune's Topline Results From IMPACT Phase 2b Trial Of Pemvidutide For Metabolic Dysfunction-Associated Steatohepatitis Showed Improvement In Antifibrotic Activity With Both Treatment Doses
Benzinga Newsdesk 10 months ago
BiotechHealth CareGeneral
Improvements observed in key non-invasive markers of fibrosis across treatment arms versus placebo, with continued reductions from 24-week timepointAdditional weight loss from 24 to 48 weeks with 1.8 mg dose,
- Improvements observed in key non-invasive markers of fibrosis across treatment arms versus placebo, with continued reductions from 24-week timepoint
- Additional weight loss from 24 to 48 weeks with 1.8 mg dose, without plateauing
- Favorable tolerability profile of pemvidutide preserved at 48 weeks, reinforced by low treatment-related discontinuation rate
- End-of-Phase 2 meeting with FDA supports advancing to registrational Phase 3 trial in MASH patients with moderate to advanced liver fibrosis